Diet, diagnosis, AS, and the management of lower-risk forms of prostate cancer

Over the years there has been a great deal of speculation (and a very small amount of data) suggesting that men who get diagnosed with relatively low-risk forms of prostate cancer may be able to delay progression of their disease by eating the right diet. … READ MORE …

But can exercise lower risk for prostate cancer diagnosis or progression?

In an incidentally timely manner, the May issue of Annals of Oncology carries a systematic review and meta-analysis of data on physical activity and risk for prostate cancer. … READ MORE …

The MEAL study — an update

Back in 2011, what is now the Alliance for Clinical Trials in Oncology (ACTO) but was then CALGB (Cancer and Leukemia Group B) initiated the Men’s Eating and Living (MEAL) study. This trial is, we hope, going to give us some real answers to a very important question: does diet affect risk for the progression of prostate cancer in men on active surveillance? … READ MORE …

Should every prostate cancer patient be on a statin?

A recent article in the Journal of Clinical Oncology, together with an associated editorial, have addressed the issue of whether evidence is now sufficient to argue that all men with prostate cancer should be treated with a statin. … READ MORE …

Age, active surveillance, and age-related risk for progression

A new report in the Journal of Clinical Oncology suggests that younger patients had a somewhat lower risk for biopsy-based Gleason score upgrade while on active surveillance (AS) than older patients. … READ MORE …

Numbers progressing and time to progression on active surveillance

A new study just published in the World Journal of Urology has provided us with data from the Prostate Cancer Outcomes Registry — Victoria (in Australia) on the progression of men initially managed on active surveillance. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …